COVID-19 research needs interactive reliable biomarkers at genomic and genetic levels. Earlier research has established the existence of genomic signature patterns and nearly perfect reliable interactive genomic biomarkers. However, reliable DNA methylation markers haven't been identified at the epigenetic level, not to mention interactiveness. This study utilized the newly proven and powerful method to discover nearly perfect interactive COVID-19 DNA methylation markers. From 865,859 methylation sites, a miniature set of seven Infinium MethylationEPIC sites (CpG sites, genes) and one intergenic region have been discovered to interact with each other and with disease subtypes. They lead to nearly perfectly (96.87% accuracy) predicting COVID-19 patients from patients presenting with respiratory symptoms but COVID-19. These seven CpG sites can jointly explain COVID-19-related diseases. These seven CpG sites and the optimum performed genomic biomarkers reported in our earlier work rise to be potential druggable targets. Among these seven CpG sites, diseases associated with cg16785077 (gene MX1) can have an incubation period of up to six to eight years, which raises a serious (or urgent) issue to investigate now or sooner.